Evolus, Inc. reaffirmed revenue guidance for full year 2022. For the period, based on its year-to-date performance and confidence in a resilient and fundamentally strong aesthetic neurotoxin market, the company continues to believe it can achieve the upper end of its full-year sales guidance range of $143 million to $150 million. This assumes a minimal contribution from international markets.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.33 USD | -2.20% | -3.08% | +7.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.60% | 725M | |
+50.70% | 795B | |
+41.96% | 627B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 294B | |
+18.02% | 245B | |
+1.27% | 222B | |
+11.95% | 215B | |
+3.68% | 160B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022